Natixis supports the efforts of Gustave Roussy to combat ovarian cancer
Gustave Roussy is organising a mystery concert in aid of the fight against ovarian cancer, in which Natixis is involved as a partner. It will take place on Wednesday 24 May at 8:30 p.m. at the Salle Gaveau to support Gustave Roussy’s research effort.
A concert for research against ovarian cancer
The World Ovarian Cancer Day takes place every year on 8 May. This event aims to raise public awareness of this cancer affecting women, which is less often talked about but which has a lower survival rate than breast cancer.
On this occasion, Natixis is a partner in the mystery concert organised by Gustave Roussy on Wednesday 24 May at 8:30 p.m. at the Salle Gaveau in aid of the fight against ovarian cancer.
A renowned coloratura soprano will perform in this mythical concert hall. The repertoire of this eclectic artist ranges from French baroque to modern music and she performs on the biggest international stages. She was involved in favour of the institute already in 2003, and then in 2011 took part in a concert featuring nearly 25 lyric artists.
On the occasion of this new concert, she will be accompanied by a great pianist and a famous jazz violinist.
> Buy your tickets online
Natixis is involved in the fight against cancer
Natixis has supported the Fondation Gustave Roussy since 2011 and is, more particularly, assisting several research teams in the fight against cancer.
Our support enables Gustave Roussy to obtain new skills and to advance research in cancer treatment in order to improve patient care and quality of life.
Because we are convinced that prevention is as important as research, we have decided to be a partner in the mystery concert organised by Gustave Roussy in aid of the fight against ovarian cancer.
We also offer our employees the possibility to take part in a conference that will be held in our offices. Dr Leary, an oncologist specialised in gynaecology with Gustave Roussy, will talk about ovarian cancer and answer all questions from our employees.
Ovarian cancer in a few figures